RESEARCH

Investigating the association between cancer and dementia risk: a longitudinal cohort study

Dan-Dan Zhang1†, Ya-Nan Ou†, Liu Yang2, Ya-Hui Ma1, Lan Tan1, Jian-Feng Feng3, Wei Cheng3 and Jin-Tai Yu2*

Abstract

Background: Previous studies found that cancer survivors had a reduced risk of dementia compared with the general population. However, these findings were uncertain because of survivor bias and a lack of stratification by cancer types. This current cohort study used data from the UK Biobank to explore these associations.

Methods: Multivariable Cox regression analyses were used to examine the association of cancer status and the risk of dementia with its subtypes after adjusting for age and sex. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated as a measure of relative risk by comparing observed dementia incidence among cancer patients.

Results: We included 263,151 participants in the observational analysis. During a median follow-up of 9.18 years, dementia was diagnosed in 472 individuals with cancer and 3685 individuals without cancer, respectively. Cancer patients had lower risks of dementia (hazard ratio: 0.89, confidence interval: 0.81–0.98) and its subtypes (Alzheimer’s disease [AD]: 0.85 [0.74–0.98]; vascular dementia [VD]: 0.81 [0.66–0.99]) in the Cox regression adjusted for age and sex. Individuals with cancers in the male genital system had substantially reduced risks of dementia (0.66 [0.46–0.93]) and AD (0.53 [0.29–0.97]) than those with cancers in other systems. Moreover, non-melanoma skin cancer and prostate cancer were associated with a reduced risk of dementia (0.79 [0.62–0.99]; 0.69 [0.49–0.97]), but not with AD or VD (P>0.05).

Conclusions: The current study supported a negative association between cancer and dementia risk, and encourages further exploration of the mechanistic basis of this inverse relationship to improve understanding.

Keywords: Alzheimer’s disease, Dementia, Vascular dementia, Cancer, Epidemiology

Background

With the aging population trend, dementia and cancer which were common in the elderly population have become major public health problems, placing a substantial burden on patients, their families, and the national healthcare systems [1, 2]. The incidence and prevalence of age-related diseases including cancer and dementia are rapidly increasing in recent years. Cancer is a major public health concern worldwide and the second leading cause of death in the USA [3]. In both sexes combined, lung cancer is the most commonly diagnosed cancer, closely followed by female breast cancer, prostate cancer, colorectal cancer, and it is also the leading cause of cancer death, followed by colorectal cancer, stomach cancer, and liver cancer [4]. Improvements in early diagnosis and treatment have ensured longer survival of cancer patients, which in turn increase the incidences of the long-term side effects such as dementia. Dementia is

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
characterized by a constant decline and deterioration of mental capacity, which inevitably impairs quality of life [5]. Generally, dementia refers to all-cause of dementia (ACD), of which Alzheimer’s disease (AD) and vascular dementia (VD) are its 2 main subtypes. Dementia prevention is of the high priority given the limited therapeutic value of drugs currently used to treat dementia [6].

Several epidemiological studies have shown reductions in risk for dementia and AD subsequent to a cancer diagnosis [7–12]. A possible explanation for the inverse relationship was that dementia and cancer had opposing pathological processes, i.e., uncontrolled cell proliferation in malignancy and neuronal cell death in dementia and AD [13–16]. An alternative explanation for this negative association is that these studies failed to take into consideration the competing risk of death in cancer patients, whose mortality rates were higher compared to individuals without cancer [17]. A recent cohort study supported this protective effect of cancer on subsequent dementia diagnosis (hazard ratio [HR]: 0.58, 95% confidence interval [CI]: 0.35–0.97) and AD diagnosis (HR: 0.45, 95%CI: [0.24–0.85]) [18]. The investigators explored the relationship between incident cancer and dementia by using illness-death models to account for survivor bias. But they cannot investigate differential effects on dementia risk according to cancer type because of the limited cases [18]. Furthermore, other studies reported similar findings but also had parallel limitations [7, 8, 10, 12, 19, 20]. These limitations included relatively short follow-up periods [7, 8, 19], small sample sizes [7, 11, 18], or a lack of information about relevant comorbidities [10, 19].

In this national cohort study, we comprehensively explored the risk for ACD, AD, and VD among patients with a cancer diagnosis compared to risk within the UK white adult population. Then we further assessed the organ specificity of the associations by mapping each cancer with the risk of dementia. And we also assessed the effect of potentially confounding factors on dementia risk among cancer patients.

Methods
This prospective cohort study was based on data from the UK Biobank study [21] that received approval from the National Information Governance Board for Health and Social Care and the National Health Service North West Multicenter Research Ethics Committee. All participants provided informed consent through electronic signature at baseline assessment.

Study population
The UK Biobank was a population-based cohort of more than 500,000 participants who attended 1 of 22 assessment centers across the United Kingdom (UK) between 2006 and 2010 [21]. The International Statistical Classification of Diseases (ICD) coding system was used to record disease diagnoses. Among 502,486 participants with available data in the cancer register, non-malignant neoplasms were not included in the definition of cancer, and non-white people were excluded. Then, individuals younger than 50 years old at baseline and those younger than 40 years old at the time of cancer diagnosis were excluded, and individuals with prevalent dementia at baseline were also excluded. Furthermore, among the remaining 319,923 eligible participants, individuals without definite dementia information diagnosis, those with cancer diagnosed after enrollment, and those with a cancer diagnosis within one year before the dementia diagnosis were excluded. The diagnosis date was the date when the ICD-10 code was first recorded in participants’ inpatient records. After applying the exclusion criteria, 263,151 participants were included in the analysis.

Ascertainment of cancer cases
We identified malignant tumors and compared dementia risk between individuals with and without a cancer history. In this study, cancer was ascertained via linkage to cancer registry and death certificate data. National cancer registries centralize information received from separate regional cancer centers around the UK. For analyses of individual cancer types and systems, we focused on the 18 specific cancers and 6 major systems with at least 100 affected individuals and at least 10 dementia cases among the affected individuals. Then we focused on the 5 cancer types with at least 1000 affected individuals as common cancers. Cancer cases within UK Biobank were identified by ICD-10 codes through linkage to the national cancer registry (C01-C97, D00-D48). To avoid potential survivor bias associated with incident cancer cases, this study was restricted to prevalent cancer cases.

Ascertainment of dementia cases
Clinical outcomes including ACD, AD, and VD diagnoses were available over a follow-up period extending up to 2021. Dementia was ascertained using hospital inpatient records containing data on admissions and diagnoses obtained from the Hospital Episode Statistics for England, Scottish Morbidity Record data for Scotland, and the Patient Episode Database for Wales. Additional cases were detected through linkage to death register data provided by the National Health Service Digital for England and Wales and the Information Services Division for Scotland. Diagnoses were recorded using the ICD-10 coding system. For the current analyses, the algorithmically defined ACD outcomes (Fields 42,018 and 42,019), AD outcomes (Fields 42,020 and 42,021), and VD outcomes (Fields 42,022 and 42,023) were used [22].
Participants with dementia were identified as having a primary/secondary diagnosis (hospital records) or underlying/contributory cause of death (death register) using ICD-9 and ICD-10 codes for AD and other dementia classifications [23]. A recent study suggested that dementia diagnoses can be reliably identified from primary care, hospital admissions, and mortality data with a positive predictive value (PPV) of 82.5% for ACD combining all data sources. PPVs for all datasets combined were 71.4% and 43.8% for AD and VD, respectively [24].

Assessment of covariates
We considered potential confounders to be any variable suspected to be linked to dementia incidence. All main models were adjusted for age at recruitment (Field 21,022) and sex (Field 31). For the extended model, we considered the following additional variables: education, categorized as higher (college/university degree or other professional qualification) or lower (Field 6138); socioeconomic status, categorized as quintiles 1, 2 to 4, and 5 (Field 189: Townsend deprivation index [combining information on social class, employment, car availability and housing]); apolipoprotein E (ApoE) ε4 carrier status (carrier/non-carrier status as defined by genetic information); body mass index (BMI, Field 21,001); smoking status (Field 20,116); alcohol consumption (Field 100,580); history of diabetes (Field 130,706–130,714); history of hypertension (Field 131,286); obesity (Field 130,792); history of heart failure (Field 131,354); and history of stroke (Field 131,368).

In addition, we adjusted for cognitive function as an additional confounder, as medical treatments for the cancer were found to cause a decline in the memory [25]. In the current study, we focused on the two tests available to the greatest number of participants (pairing and reaction time) to reflect cognitive function. Pair matching (PM, Field 399) and reaction time (RT, Field 20,023) measure visual memory and reaction ability, respectively, with higher scores reflecting worse cognitive function (continuous scores).

Statistical analysis
All participants were followed up from the date of recruitment until that of dementia diagnosis, death, loss to follow-up, or the end of the study period (November 6, 2021), whichever occurred first. Individuals with prevalent cancer reported at baseline enrollment were classified as the exposure group. Baseline characteristics of the analytic sample were summarized across cancer status as a percentage for categorical variables and mean and standard deviation (SD) for continuous variables.

Multivariable Cox regression analyses were used to examine the associations of cancer status with incident ACD, AD, and VD. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated as a measure of relative risk by comparing the observed dementia incidence among cancer patients with that of non-cancer participants. Two multivariable models were adjusted for different variables. Model 1 adjusted for age and sex. To examine whether the association of dementia with cancer was attributable to lifestyle factors and other health-related factors, model 2 was additionally adjusted for education, socioeconomic status, ApoE4, BMI, smoking status, alcohol consumption, obesity, hypertension, diabetes, heart failure, and stroke.

We conducted several sensitivity analyses. To explore the effect of cognitive function on the incidence of dementia in participants, we additionally adjusted for cognitive function (PM and RT). To determine the potential differential effect of cancer on dementia type, three definitions of the outcome were compared: (1) all-cause dementia; (2) AD dementia; and (3) vascular dementia. The cumulative incidence curve for each cohort was measured using the Kaplan–Meier method, and the curve difference was calculated using the log-rank test. Since cancer is a significant risk factor for death, it was necessary to test the possible influence of competing events on the association between cancer and the risk of dementia by applying Fine and Gray’s sub-distribution hazards regression model [26]. The competing event was defined as death. We also performed subgroup analyses stratified by baseline characteristics of the participants. In addition, we conducted separate subgroup analyses according to whether participants had non-melanoma skin cancer [NMSC] or other cancers except NMSC, whether the cancer is related to smoking-related cancers (oral, pharynx, larynx, esophagus, stomach, pancreas, bronchus or lung, cervix uteri, bladder, and kidney) [27], or not, and whether participants had a cancer in 18 specific organs or a cancer in 6 major systems. P values were 2-sided with statistical significance set at less than 0.05. All statistical analyses were performed using R statistical software, version 4.1.1.

Results
Characteristics of the study population
At baseline, 502,486 participants were screened. After applying the exclusion criteria, 263,151 participants were included in our study (Fig. 1). The mean age at recruitment was 60.27 (SD: 5.40) years, and 142,824 participants (54.27%) were female. The median follow-up was 9.28 (interquartile range [IQR]: 5.55–13.01) years for cancer patients and 9.17 (IQR: 5.65–12.69) years for non-cancer patients. Baseline characteristics of participants were shown in Table 1.
Model 1 was adjusted for age and sex and model 2 was additionally adjusted for education, socioeconomic status, ApoE4, BMI, smoking status, alcohol consumption, obesity, hypertension, diabetes, heart failure, and stroke. After adjustment for demographic characteristics (age, sex, education, socioeconomic status), BMI, smoking status, and alcohol consumption were included in model 2, taking into account the established effects on cancer-related mortality [18]. In addition, ApoE4 and some comorbidities (obesity, hypertension, diabetes, heart failure, and stroke) were also included in model 2 as risk factors for dementia [8, 28]. The subgroup analyses and sensitivity analyses in the article were based on Model 2.

Risk of dementia after cancer
We included 26,095 participants with a history of cancer at baseline, among whom 472 participants developed ACD, 208 developed AD, and 103 developed VD during the follow-up (Table 1). We investigated the association of cancer with dementia and its subtypes risks by using Cox regression models (Fig. 2). In model 1, the risk of dementia and its subtypes among patients with a cancer history were lower compared to those without a cancer history. Compared with non-cancer patients, HRs (95% CI) for risks of ACD, AD, and VD among patients with cancer were 0.89 (0.81–0.98), 0.85 (0.74–0.98), and 0.81 (0.66–0.99), respectively. In Cox model 2, the inverse association of cancer with ACD (0.87 [0.76–0.98]) and VD (0.74 [0.55–0.98]) risk were still significant (Fig. 2). After additional adjustments for cognitive function, cancer was only associated with a reduced risk of ACD (0.86 [0.76–0.98]), but not AD or VD (P>0.05) (Supplementary Table 1).
To further investigate the effects of confounding factors on the association between cancer and the risk of dementia, a series of subgroup analyses stratified by age, sex, *ApoE4* status, smoking status, alcohol consumption, BMI [29], and follow-up period were conducted (Fig. 3). These analyses were all adjusted for age, sex, education, socioeconomic status, *ApoE4*, BMI, smoking status, alcohol consumption, obesity, hypertension, diabetes, heart failure, and stroke. The inverse association between cancer and ACD risk was more pronounced in individuals aged over 60 years old (0.87 [0.76–1.00]), males (0.79 [0.66–0.95]), those without smoking history (0.80 [0.66–0.97]), those with a BMI between 25 and 30 (0.74 [0.60–0.92]), or those with a follow-up of more than 10 years (0.68 [0.53–0.89]). A significant inverse association was observed between cancer and AD risk in individuals with *ApoE4* non-carriers (0.68 [0.48–0.97]), individuals without smoking history (0.69 [0.51–0.93]), or those with a BMI between 25 and 30 (0.69 [0.50–0.95]). In addition, the same pattern of associations was also pronounced between cancer and VD risk in individuals aged over 60 years old (0.73 [0.54–0.98]), males (0.66 [0.45–0.97]), *ApoE4* non-carriers (0.56 [0.36–0.89]), those with smoking history (0.59 [0.39–0.89]), those with alcohol history (0.72 [0.54–0.98]), or those with a BMI over 30 (0.48 [0.24–0.94]).

**Table 1** Study characteristics of analytical sample stratified by cancer status

| Characteristics                        | Participants with cancer history (n=26,095 ) | Participants without cancer history (n=237,056 ) |
|----------------------------------------|-------------------------------------------|-----------------------------------------------|
| Age at cancer diagnosis, mean (SD), years | 62.14 (5.02)                              | 60.07 (5.40)                                  |
| BMI, mean (SD)                         | 27.47 (4.70)                               | 27.68 (4.78)                                  |
| Age at entry, n (%)                    |                                           |                                               |
| 50–60 years                            | 7201 (27.60)                               | 102,718 (43.33)                               |
| ≥60 years                              | 18,894 (72.40)                             | 134,338 (56.67)                               |
| Sex (female, %)                        | 15,348 (58.81)                             | 127,476 (53.77)                               |
| ApoE4 carrier                          | 7088 (27.16)                               | 65,523 (27.64)                                |
| College, n (%)                         |                                           |                                               |
| Yes                                    | 11,101 (42.54)                             | 103,445 (43.64)                               |
| No                                     | 8310 (31.85)                               | 78,651 (33.18)                                |
| Unknown                                | 6684 (25.61)                               | 54,960 (23.18)                                |
| Smoking, n (%)                         |                                           |                                               |
| Never                                  | 13,111 (50.24)                             | 124,033 (52.32)                               |
| Previous                               | 10,678 (40.92)                             | 89,766 (37.87)                                |
| Current                                | 2182 (8.36)                                | 22,317 (9.41)                                 |
| Unknown                                | 124 (0.48)                                 | 940 (0.40)                                    |
| Alcohol, n (%)                         |                                           |                                               |
| Never                                  | 1069 (4.10)                                | 8376 (3.53)                                   |
| Previous                               | 1026 (3.93)                                | 8704 (3.67)                                   |
| Current                                | 23,972 (91.86)                             | 219,753 (92.70)                               |
| Unknown                                | 28 (0.11)                                  | 223 (0.09)                                    |
| Co-morbidities, n (%)                  |                                           |                                               |
| Diabetes                               | 3026 (11.60)                               | 24,973 (10.53)                                |
| Hypertension                           | 11,686 (44.78)                             | 92,207 (38.90)                                |
| Stroke                                 | 1997 (7.65)                                | 14,857 (6.27)                                 |
| Obesity                                | 2800 (10.73)                               | 26,007 (10.97)                                |
| Heart failure                          | 5922 (22.69)                               | 44,007 (18.56)                                |
| Follow-up years, median (interquartile range) | 9.28 (5.55–13.01) | 9.17 (5.65–12.69) |
| Types of dementia                      |                                           |                                               |
| ACD, n (%)                             | 472 (1.81)                                 | 3685 (1.55)                                   |
| AD, n (%)                              | 208 (0.80)                                 | 1670 (0.70)                                   |
| VD, n (%)                              | 103 (0.39)                                 | 862 (0.36)                                    |

**Abbreviations:** BMI body mass index, ACD all-cause dementia, AD Alzheimer’s disease, VD vascular dementia
In Kaplan-Meier analysis, the log-rank test showed a difference between the populations being studied in the probability of ACD at any time point, lacking significant differences in the probability of AD and VD (Supplementary Fig. 1). As shown in Supplementary Fig. 2, the cumulative incidences of dementia remained statistically different between cancer and non-cancer groups after controlling for competing risks of death.

**Risk of dementia in different cancer sites and systems**

To further explore the correlation between cancer and dementia risk, we stratified cancer into subgroups of

### Table 1: Characteristics of cancer and dementia

| Characteristic | Total No. of participants | ACD (HR 95%CI P Value) | AD (HR 95%CI P Value) | VD (HR 95%CI P Value) |
|----------------|---------------------------|-------------------------|------------------------|------------------------|
| Age 50-60 y    | 109919                    | 0.82 [0.51, 1.30] 0.307 | 0.84 [0.28, 1.45] 0.282 | 0.81 [0.25, 2.61] 0.721 |
| ≥60 y          | 153232                    | 0.87 [0.76, 1.00] 0.042 | 0.88 [0.73, 1.07] 0.207 | 0.73 [0.54, 0.98] 0.039 |
| Sex Male      | 120327                    | 0.79 [0.66, 0.95] 0.013 | 0.82 [0.62, 1.08] 0.157 | 0.66 [0.45, 0.97] 0.036 |
| Female        | 142624                    | 0.95 [0.80, 1.14] 0.581 | 0.90 [0.70, 1.17] 0.433 | 0.88 [0.57, 1.35] 0.546 |
| ApoE4 Carrier | 72611                     | 0.89 [0.70, 1.06] 0.196 | 0.97 [0.78, 1.22] 0.802 | 0.92 [0.63, 1.33] 0.647 |
| Non-carrier    | 181953                    | 0.84 [0.70, 1.02] 0.079 | 0.88 [0.68, 1.13] 0.233 | 0.56 [0.36, 0.89] 0.014 |
| Smoking Yes   | 124943                    | 0.92 [0.78, 1.09] 0.357 | 1.03 [0.81, 1.32] 0.804 | 0.59 [0.39, 0.89] 0.012 |
| No            | 137144                    | 0.80 [0.68, 0.97] 0.022 | 0.89 [0.51, 1.03] 0.133 | 0.93 [0.62, 1.36] 0.713 |
| Alcohol Yes   | 253455                    | 0.88 [0.78, 1.01] 0.061 | 0.87 [0.72, 1.06] 0.164 | 0.72 [0.54, 0.98] 0.035 |
| No            | 9445                      | 0.58 [0.31, 1.08] 0.086 | 0.85 [0.26, 1.66] 0.370 | 0.97 [0.33, 2.86] 0.958 |
| BMI 18.5-25   | 79160                     | 1.06 [0.87, 1.30] 0.534 | 1.08 [0.82, 1.43] 0.586 | 1.05 [0.67, 1.64] 0.625 |
| 25-30         | 113745                    | 0.74 [0.60, 0.92] 0.005 | 0.69 [0.50, 0.90] 0.023 | 0.69 [0.44, 1.11] 0.124 |
| ≥30           | 67812                     | 0.83 [0.63, 1.10] 0.189 | 0.89 [0.58, 1.36] 0.587 | 0.48 [0.24, 0.94] 0.033 |
| Follow-up period 0-5 y | 20463                   | 0.78 [0.58, 1.05] 0.102 | 0.77 [0.47, 1.25] 0.288 | 0.66 [0.34, 1.28] 0.226 |
| 5-10 y        | 148452                    | 0.95 [0.80, 1.12] 0.513 | 0.97 [0.76, 1.24] 0.809 | 0.86 [0.56, 1.35] 0.421 |
| ≥10 y         | 94236                     | 0.88 [0.53, 0.89] 0.004 | 0.85 [0.58, 1.24] 0.393 | 0.65 [0.35, 1.22] 0.183 |

**Fig. 2** Multi-state results: HRs and 95% CIs of cancer on the transition to dementia. Model 1 adjusted for age at study entry, and sex. Model 2 further adjusted for education, BMI, ApoE4, smoking status, alcohol consumption, socioeconomic status, diabetes, hypertension, heart failure, obesity, and stroke. Abbreviations: HR, hazard ratios; CI, confidence interval; ACD, all-cause dementia; AD, Alzheimer’s disease; VD, vascular dementia

**Fig. 3** Risk Factors associated with dementia development using the robust inference for the Cox regression. *Calculated using Cox proportional hazards modeling, adjusted for age, sex, education, ApoE4, socioeconomic status, BMI, smoking status, alcohol consumption, diabetes, hypertension, heart failure, obesity, and stroke. Abbreviation: ACD, all-cause dementia; AD, Alzheimer’s disease; VD, vascular dementia; HR, hazard ratios; CI, confidence interval
cancers in 6 different systems: lymphohematopoietic system, digestive system, endocrine system, reproductive system (including male genital system and female genital system), respiratory system, and urinary system. We observed that in Cox model 2, only the reproductive system cancer was associated with a lower risk of ACD (0.75 [0.57–1.00]), but not with AD or VD risk (P>0.05). However, cancer patients of the male genital system had substantially reduced risks of ACD (0.66 [0.46–0.93]) and AD (0.53 [0.29–0.97]) (Fig. 4).

In sensitivity analyses, no matter whether it is related to smoking, any cancer (except NMSC) was associated with risk of incident dementia (Supplementary Table 2). Moreover, we assessed the associations of specific cancer sites with dementia risk. In Cox model 2, compared with non-cancer patients, only NMSC and prostate cancer (PC) patients were associated with a lower risk of ACD (NMSC: 0.79 [0.62–0.99]; PC: 0.69 [0.49–0.97]), but not with AD and VD (Supplementary Table 2).

In addition, we stratified our results by age, smoking status, alcohol consumption, ApoE4 status, and BMI to explore the association between 5 common cancers and dementia risk (Table 2, Supplementary Table 3). In individuals over 60 years old, NMSC and PC patients showed a decreased ACD risk (NMSC: 0.78 [0.61–0.99]; PC: 0.70 [0.49–0.99]), but no observed differences in AD and VD risk. In various subgroups stratified by smoking status, colon cancer patients without a smoking history had

![Fig. 4](image-url) Association of system-specific cancers with dementia and its subtypes. *Calculated using Cox proportional hazards modeling, adjusted for age, sex, education, ApoE4, socioeconomic status, BMI, smoking status, alcohol consumption, diabetes, hypertension, heart failure, obesity, and stroke. — The number of people diagnosed with ACD, AD, or VD in the type of cancer patients is too small to calculate the HR value. Abbreviation: ACD, all-cause dementia; AD, Alzheimer’s disease; VD, vascular dementia; HR, hazard ratios; CI, confidence interval; LHS, lymphohematopoietic system; DS, digestive system; ES, endocrine system; RPS, reproductive system; MGS, male genital system; FGS, female genital system; RS, respiratory system; US, urinary system
an increased risk of VD (3.64 [1.49–8.88]), and NMSC patients with a smoking history had decreased risks of ACD (0.67 [0.48–0.95]) and VD (0.34 [0.13–0.93]). NMSC was associated with VD risk (0.51 [0.27–0.95]) and PC was associated with ACD risk (0.70 [0.50–1.00]) in the drinkers (Table 2). In addition, NMSC was associated with VD risk (0.34 [0.13–0.93]) among patients without ApoE4. Melanoma of skin cancer was associated with increased AD (2.77 [1.03–7.45]) and VD (4.48 [1.10–18.32]) risks among patients with BMI between

Table 2  Association of specific cancer sites with dementia by age, smoking status, and alcohol status

| Specific cancer sitesa | Participants with cancer history (N) | ACD |  |  | AD |  |  | VD |  |  |
|---|---|---|---|---|---|---|---|---|---|---|
|  |  | HRb | 95% CI | P-value | HRb | 95% CI | P-value | HRb | 95% CI | P-value |
| Age <60 years |  |  |  |  |  |  |  |  |  |  |
| Breast | 2189 | 0.73 | 0.27–1.98 | 0.538 | 0.41 | 0.06–2.97 | 0.378 | 3.43 | 0.78–15.03 | 0.103 |
| Colon | 254 | - | - | - | - | - | - | - | - |
| Melanoma of skin | 350 | 0.82 | 0.12–5.87 | 0.847 | 1.98 | 0.28–12.20 | 0.497 | - | - |
| NMSC | 1665 | 0.97 | 0.43–2.17 | 0.936 | 0.77 | 0.19–3.12 | 0.715 | - | - |
| Prostate | 334 | 0.67 | 0.09–4.77 | 0.686 | - | - | - | - |
| Age ≥60 years |  |  |  |  |  |  |  |  |  |  |
| Breast | 4493 | 1.04 | 0.79–1.36 | 0.787 | 0.95 | 0.63–1.41 | 0.783 | 0.90 | 0.46–1.76 | 0.751 |
| Colon | 767 | 0.89 | 0.49–1.62 | 0.712 | 0.76 | 0.29–2.04 | 0.590 | 1.73 | 0.72–4.19 | 0.223 |
| Melanoma of skin | 719 | 1.14 | 0.64–2.01 | 0.655 | 1.26 | 0.57–2.82 | 0.567 | 0.86 | 0.21–3.44 | 0.828 |
| NMSC | 5199 | 0.78 | 0.61–0.99 | 0.038 | 0.79 | 0.55–1.12 | 0.184 | 0.60 | 0.34–1.06 | 0.080 |
| Prostate | 2378 | 0.70 | 0.49–0.99 | 0.044 | 0.58 | 0.32–1.06 | 0.077 | 0.56 | 0.26–1.19 | 0.130 |
| Smoking |  |  |  |  |  |  |  |  |  |  |
| Breast | 2969 | 1.24 | 0.86–1.78 | 0.243 | 1.18 | 0.70–1.99 | 0.538 | 1.20 | 0.52–2.74 | 0.671 |
| Colon | 556 | 0.57 | 0.21–1.52 | 0.680 | 0.35 | 0.05–2.46 | 0.289 | - | - |
| Melanoma of skin | 440 | 1.51 | 0.75–3.02 | 0.248 | 1.80 | 0.67–4.81 | 0.244 | 0.72 | 0.10–5.13 | 0.741 |
| NMSC | 3267 | 0.67 | 0.48–0.95 | 0.025 | 0.74 | 0.45–1.23 | 0.245 | 0.34 | 0.13–0.93 | 0.035 |
| Prostate | 1461 | 0.73 | 0.47–1.14 | 0.164 | 0.65 | 0.31–1.38 | 0.263 | 0.87 | 0.41–1.85 | 0.710 |
| Non-smoking |  |  |  |  |  |  |  |  |  |  |
| Breast | 3682 | 0.83 | 0.56–1.22 | 0.339 | 0.68 | 0.37–1.23 | 0.202 | 0.93 | 0.38–2.31 | 0.884 |
| Colon | 459 | 1.03 | 0.49–2.18 | 0.930 | 1.03 | 0.33–3.19 | 0.965 | 3.64 | 1.49–8.88 | 0.004 |
| Melanoma of skin | 627 | 0.78 | 0.32–1.87 | 0.572 | 1.02 | 0.33–3.16 | 0.978 | 0.80 | 0.11–5.68 | 0.819 |
| NMSC | 3577 | 0.89 | 0.66–1.22 | 0.481 | 0.80 | 0.50–1.29 | 0.365 | 0.80 | 0.39–1.62 | 0.527 |
| Prostate | 1233 | 0.63 | 0.36–1.09 | 0.096 | 0.43 | 0.16–1.17 | 0.097 | - | - |
| Alcohol |  |  |  |  |  |  |  |  |  |  |
| Breast | 6309 | 1.09 | 0.83–1.42 | 0.529 | 0.92 | 0.61–1.38 | 0.682 | 1.16 | 0.63–2.15 | 0.627 |
| Colon | 984 | 0.83 | 0.46–1.50 | 0.536 | 0.71 | 0.27–1.90 | 0.494 | 1.60 | 0.66–3.88 | 0.293 |
| Melanoma of skin | 1023 | 1.18 | 0.68–2.04 | 0.550 | 1.41 | 0.67–2.98 | 0.361 | 0.82 | 0.20–3.28 | 0.776 |
| NMSC | 6618 | 0.81 | 0.64–1.02 | 0.070 | 0.79 | 0.56–1.12 | 0.189 | 0.51 | 0.27–0.95 | 0.034 |
| Prostate | 2639 | 0.70 | 0.50–1.00 | 0.051 | 0.59 | 0.32–1.07 | 0.082 | 0.58 | 0.27–1.22 | 0.149 |
| Non-alcohol |  |  |  |  |  |  |  |  |  |  |
| Breast | 362 | 0.29 | 0.07–1.18 | 0.084 | 0.62 | 0.14–2.67 | 0.523 | - | - |
| Colon | 37 | - | - | - | - | - | - | - |
| Melanoma of skin | 46 | - | - | - | - | - | - | - |
| NMSC | 240 | 0.43 | 0.11–1.77 | 0.244 | 0.60 | 0.08–4.38 | 0.615 | 1.81 | 0.42–7.90 | 0.429 |
| Prostate | 71 | 0.50 | 0.07–3.74 | 0.502 | - | - | - | - |

Bold text indicates a p-value less than 0.05, which is statistically significant

− The number of people diagnosed with ACD, AD, or VD in the types of cancer is too small to calculate the HR

Abbreviations: ACD all-cause dementia, AD Alzheimer’s disease, VD vascular dementia, HR hazard ratios, CI confidence interval, NMSC non-melanoma skin cancer

a Common cancer and more than 1000 people with cancer

b Calculated using Cox proportional hazards modeling, adjusted for age, sex, education, ApoE4, socioeconomic status, BMI, smoking status, alcohol consumption, diabetes, hypertension, heart failure, obesity, and stroke
18 and 25, but NMSC was associated with ACD (0.66 [0.45–0.97]) risk among those with BMI between 25 and 30 (Supplementary Table 3).

Discussion
Summary of results
In this nationwide prospective cohort study, our results showed that cancer was associated with modestly reduced risks of ACD and VD after adjusting for common dementia risk factors. Subgroup analyses showed that the association of cancer with subsequent dementia risk was more pronounced in older people, males, non-carriers of ApoE4, and those with higher BMI. In addition, we observed that reproductive system cancer was associated with a lower risk of ACD, whereas male genital system cancer had strong inverse associations with both ACD and AD risks. Then NMSC and PC were associated with a lower risk of ACD.

Comparison with previous literature
Several studies have investigated the relationship between cancer and dementia especially AD, yielding inconsistent findings. Some reported inverse associations [18–20], while others revealed positive [30, 31] or null connections [7, 28]. Our results supported that cancer was related to a lower risk of dementia was consistent with a review of previous experimental studies, prospective cohort studies, and meta-analyses [32]. Similar to the results of Ord- ing et al. and Sun et al. [12, 20], the current study found a stronger association between cancer and the risk of ACD and VD compared to AD after further adjustment for other potentially confounding factors besides age and sex. Similar to our results, a recent prospective cohort study showed that cancer was associated with a roughly 42% reduction in risk of dementia and a 55% reduction in risk of AD [18]. In addition, a study from the Utah Population Database argued that the inverse association between cancer and AD risk arose from bias due to the competing risks of death [17]. However, this association remained stable after controlling for competing risks of death in this study. Similarly, one recent study also suggested that the bias induced by selective survival in simulations was too small to explain the observed inverse cancer-dementia link [33]. Previous studies showed that medical treatments for the cancer would cause a decline in the memory [34, 35]. However, we found an inverse association between cancer and ACD risk after adjusting for cognitive function. The effect of cognitive function on the relationship between cancer and dementia risk was not found in the present study.

Driver et al. found that patients with smoking-related cancers had a lower risk of probable AD than those with non-smoking-related cancer [11], but there were no correlations between smoking-related cancers and dementia risk in our study. This inconsistency might be due to our adjustment for additional confounders. Consistent with the study of Ord- ing et al. and we had found that cancer was found to be protective against dementia when individuals aged over 60 years old. This may be explained by the fact that aging is a common risk factor for both dementia [36] and cancer [37]. Compared with previous studies, the present study included more subgroup analyses of cancer types and systems to further explore the correlation between cancer and dementia risk. Our findings showed that patients of male genital system cancer had lower risks of dementia and AD because of the inverse association between prostate cancer and dementia. Previous related studies produced inconsistent results, possibly due to the differences in sample size between studies [20, 31]. A recent cohort study reported the inverse association between NMSC and dementia is stronger for ACD than for other dementia types [38], which was consistent with the current study. However, we found no significant association between other cancers and AD after excluding NMSC, which was inconsistent with Driver et al. [11]. This may be due to their smaller sample size and correction factors.

Several studies investigated whether cancer treatment modulates the risk of dementia. Cancer treatment might be associated with a cancer diagnosis, and also might engender temporary effects on cognition like “chemobrain” [39]. Although chemotherapy might impair cognitive function, there is no clear evidence linking chemotherapy with an increased risk of dementia. Baxter et al. [40] and Du et al. [41] found patients receiving chemotherapy had a reduced dementia risk, which might be explained that chemotherapy can protect neurons susceptible to AD by inhibiting inflammation [42]. Recent evidence found that anti-cancer drugs targeting mTOR slow AD progression by reducing iron accumulation, suggesting that selective anticancer drugs might have a modulating effect on AD pathophysiology [43]. Recent meta-analyses showed that individuals with prostate cancer who received androgen deprivation therapy (ADT) had an increased risk of subsequent dementia [44, 45]. This was contrary to our findings on prostate cancer on dementia risk. Therefore, whether or not to receive cancer treatment might have an impact on the risk of dementia after a cancer diagnosis.

Potential mechanisms
Although cancer patients might have some protection from dementia, the underlying pathophysiological mechanism was not yet clearly defined. The inverse association between cancer and dementia might be related to differential regulation of common genes and pathways. In
cancer, cell regulation mechanisms were disrupted with increased cell survival and/or proliferation, whereas AD, in contrast, was associated with increased neuronal death caused by or accompanied by deposition of amyloid-beta (Aβ) and tau. Gene polymorphisms, DNA methylation, or other mechanisms that induce changes in molecular activity play critical roles in the decision to “repair and live”- or “die” and may be involved in the pathogenesis of both diseases [13]. For example, a recent review proposes that several molecular players, namely p53 and PIN1, may be involved in complex molecular interaction associated with this inverse correlation [37]. The prototypical tumor suppressor protein p53 plays opposite roles in the pathological development of cancer and dementia due to the abnormal activation of other proteins [37]. As seen in polymorphisms of p53, a genetic predisposition to anti-apoptosis might protect individuals from cancer while increasing the risk of neurodegeneration [46]. The protein Pin1 is a ubiquitous enzyme that has been shown to regulate a diverse array of cellular processes of cell proliferation and differentiation [47]. Many tumors such as prostate and lung cancer in humans over-express Pin1 [48], whereas its expression in AD patient’s brain is very low [37]. Single nucleotide polymorphisms (SNPs) in the promoter region of the Pin1 gene that inhibit Pin1 expression are associated with increased AD risk [49] and decreased cancer risk [50]. Taken together, these findings provide evidence for a true protective role of cancer in reducing dementia risk.

**Strengths and limitations**

There were several strengths and limitations of this population cohort study. Major strengths of the current study were its large sample size of UK Biobank participants, the prospective design, and long-term follow-up. All cancer and dementia patients were identified from the nationwide databases with high accuracy and coverage. The use of nationally registered data can guarantee the integrity of the data. In addition, the UK Biobank cohort collected extensive information on behaviors, sociodemographic risk factors, and disease history, allowing adjustment for potential confounders associated with dementia. These approaches limited potential problems with selection bias, sample size, and generalizability. Due to the large sample size, we were able to investigate potential differential effects on dementia risk according to cancer sites and systems. Moreover, we adjusted for various dementia risk factors that may confound the association of cancer with dementia.

This study also had some limitations. First, dementia diagnoses were obtained from registry-based data rather than detailed neuropsychological assessments. Although the overall accuracy of obtaining dementia diagnoses through registries is good [24], there is still the potential to misclassify some study participants. Furthermore, although there is evidence that the rate of false positives is relatively low, the rate of false negatives is still largely unknown [24]. Second, the number of dementia cases was small for some rare cancer types. Third, the relatively young age of the cohort limited the number of cases of dementia, especially AD, thus limiting our ability to identify correlations. Forth, we lacked information on the cancer treatment history of the participants. During the follow-up period, cancer survivorship and dementia diagnosis rate showed differences between participants with and without cancer treatment. Finally, the present analyses were performed only within individuals of white British descent and hence findings might not be generalizable to other ethnicities and general populations. It cannot be used to provide representative disease prevalence and incidence rates. Nevertheless, an effective assessment of exposure-disease correlations is generalizable and does not require participants to be representative of the entire population [51].

**Conclusions**

In conclusion, the findings from this large cohort study were consistent with previous studies that cancer was associated with a reduction in the risk of dementia. This study showed that NMSC and PC were associated with reduced dementia risk. Future research is required to further explore the mechanistic basis of this relationship to improve understanding of the mechanisms underlying this negative association. In addition, investigating the potential impact of cancer treatment on dementia risk is another interesting area for future work.

**Abbreviations**

HRs: Hazard ratios; CIs: Confidence intervals; ACD: All cause dementia; AD: Alzheimer’s disease; VD: Vascular dementia; The UK: The United Kingdom; ICD: The International Statistical Classification of Diseases; PPV: Positive predictive value; ApoE4: Apolipoprotein E 4; BMI: Body mass index; SD: Standard deviation; NMSC: Non-melanoma skin cancer; IQR: Interquartile range; PC: Prostate cancer; ADT: Androgen deprivation therapy; Aβ: Amyloid-beta; SNPs: Single nucleotide polymorphisms.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13195-022-01090-9.

**Additional file 1:** Supplementary Figure 1. Kaplan-Meier analysis for the cumulative incidence of dementia with log-rank test. **Supplementary Figure 2.** The survival curves of cumulative incidence of dementia and competing risk event for death. **Supplementary Table 1.** Association of cancer with dementia risk after additional adjustment for cognitive function. **Supplementary Table 2.** Association of site-specific cancers with dementia and its subtypes. **Supplementary Table 3.** Association of specific cancer sites with ACD, AD, and VD by ApoE4 status and BMI.
Acknowledgements
This study utilized the UK Biobank Resource under application number 19542. We would like to thank all the participants and researchers from the UK Biobank.

Authors’ contributions
Concept and design: JTY and WC; acquisition, analysis, or interpretation of data: all authors; drafting of the manuscript: DDZ and YNO; critical revision of the manuscript for important intellectual content: all authors; statistical analysis: DDZ and YNO; chart design: DDZ and YNO; obtained funding: JTY; administrative, technical, or material support: LT and JTY; the author(s) read and approved the final manuscript.

Funding
This study was supported by grants from the National Natural Science Foundation of China (82071201, 91840026, 82071997), the Shanghai Rising Star Program (No. 21QA1408700), Shanghai Municipal Science and Technology Major Project (No.2018SHZDKZ01), Research Start-up Fund of Huashan Hospital (2022QD002), Excellence 2025 Talent Cultivation Program at Fudan University (3030277001), and ZHANGJIANG LAB, Tianqiao and Chrissy Chen Hospital (2022QD002), Excellence 2025 Talent Cultivation Program at Fudan University, Shanghai, 12th Wulumuqi Zhong Road, Shanghai 200040, China. 3 Institute of Science and Technology for Brain-inspired Intelligence, Fudan University, Shanghai, China. 2 Department of Neurology and Institute of Neurology, Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, 12th Wulumuqi Zhong Road, Shanghai 200040, China. 1 Institute of Science and Technology for Brain-inspired Intelligence, Fudan University, Shanghai, China.

Availability of data and materials
The datasets described in this manuscript are available from the UK Biobank with an approved protocol under the project number of 19,542. External investigators can request the data and approval of use on application to the UK Biobank (www.ukbiobank.ac.uk/).

Declarations
Ethics approval and consent to participate
The UKB study received approval from the National Health Service (NHS) North West Multicenter Research Ethics Committee. All participants provided written informed consent according to the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. 2Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOR, Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, 12th Wulumuqi Zhong Road, Shanghai 200040, China. 3Institute of Science and Technology for Brain-inspired Intelligence, Fudan University, Shanghai, China.

Received: 29 April 2022 Accepted: 16 September 2022
Published online: 05 October 2022

References
1. Livingston G, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734.
2. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
4. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
5. Iadecola C, et al. Vascular cognitive impairment and dementia. JACC scientific expert panel. J Am Coll Cardiol. 2019;73(25):3326–44.
6. Zhang Y, et al. Consumption of coffee and tea and risk of developing stroke, dementia, and poststroke dementia: a cohort study in the UK Biobank. PLoS Med. 2021;18(11):e1005830.
7. Roe CM, et al. Alzheimer disease and cancer. Neurology. 2015;85(5):895–8.
8. Roe CM, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74(2):106–12.
9. Lin HL, et al. Inverse association between cancer and dementia: a population-based registry study in Taiwan. Alzheimer Dis Assoc Disord. 2016;30(2):118–22.
10. Friedman DM, et al. Associations between cancer and Alzheimer’s disease in a U.S. Medicare population. Cancer Med. 2016;5(10):2965–76.
11. Driver JA, et al. Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.
12. Ording AG, et al. Cancer and risk of Alzheimer’s disease: small association in a nationwide cohort study. Alzheimers Dement. 2020;17:127.
13. Behrens MJ, Lendron C, Roe CM. A common biological mechanism in cancer and Alzheimer’s disease? Curr Alzheimer Res. 2009;6(3):196–204.
14. Ibáñez K, et al. Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet. 2014;10(2):e1004173.
15. Driver JA, Lu KP, Pin1: a new genetic link between Alzheimer’s disease, cancer and aging. Curr Aging Sci. 2010;3(3):158–65.
16. Tabarés-Seisdedos R, et al. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol. 2011;12(6):604–8.
17. Hanson HA, et al. Is cancer protective for subsequent Alzheimer’s disease risk? Evidence from the Utah population database. J Gerontol B Psychol Sci Soc Sci. 2017;72(6):1032–43.
18. Chamberlain JD, et al. Investigating the association between cancer and the risk of dementia: results from the Memento cohort. Alzheimers Dement. 2021;17(9):1415–21.
19. Muscico M, et al. Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology. 2013;87(7):814(4):322–8.
20. Sun M, et al. The association between cancer and dementia: a national cohort study in Sweden. Front Oncol. 2020;4:848.
21. Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
22. Wilkinson T, et al. Identifying dementia cases with routinely collected health data: a systematic review. Alzheimers Dement. 2018;14(8):1038–51.
23. Lourida L, et al. Association of lifestyle and genetic risk with incidence of dementia. JAMA. 2019;322(5):430–7.
24. Wilkinson T, et al. Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur J Epidemiol. 2019;34(6):557–65.
25. Lyall DM, et al. Cognitive test scores in UK Biobank: data reduction in 480,416 participants and longitudinal stability in 20,346 participants. PLoS One. 2016;11(4):e0154222.
26. Meguro K, Team KP The validity of the Basic Checklist in the old-old population: the Kihara Project. Jpn J Geriatr Psychiatry. 2012;23(6):725–30.
27. National Center for Chronic Disease, P, S Health Promotion Office on, and Health. Reports of the Surgeon General. In: The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta: Centers for Disease Control and Prevention (US); 2014.
28. Bowles EJA, et al. Risk of Alzheimer’s disease following a cancer diagnosis. Alzheimers Dement. 2017;2.74. 13(7):PS16.
29. Weir CB, Jan A. BMI classification percentile and cut off points. In: The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta: Centers for Disease Control and Prevention (US); 2014.
30. Frain L, et al. Association of cancer and Alzheimer’s disease risk in a national cohort of veterans. Alzheimers Dement. 2017;13:127. 13(12):1364–70.
31. Kang J, et al. Risk of dementia in prostate cancer survivors: a nationwide cohort study in Korea. Curr Probl Cancer. 2020:32.264. 44(6):100578.
32. Solomon L, Solomons J, Gosney M. Dementia and cancer: a review of the literature and current practice. Aging Health. 2013;9(3):307–19.
33. Hayes-Larson E, et al. The competing risk of death and selective survival cannot fully explain the inverse cancer-dementia association. Alzheimers Dement. 2020;16(12):1696–703.
34. Ando-Tanabe N, et al. Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer. 2014;21(4):453–62.
35. Chen X, et al. Cognitive function in breast cancer patients on chemotherapy: a longitudinal study. Zhonghua Yi Xue Za Zhi. 2014;94(1):27–30.
36. Ott A, et al. Incidence and risk of dementia. The Rotterdam study. Am J Epidemiol. 1998;147(6):574–80.
37. Lanni C, et al. Cancer and Alzheimer’s disease inverse relationship: an age-associated diverging derailment of shared pathways. Mol Psychiatry. 2021;26(1):280–95.
38. Schmidt SA, et al. Non-melanoma skin cancer and risk of Alzheimer’s disease and all-cause dementia. PLoS One. 2017;12(2):e0171527.
39. Nguyen LD, Ehrlich BE. Cellular mechanisms and treatments for chemo-brain: insight from aging and neurodegenerative diseases. EMBO Mol Med. 2020;12(6):e12075.
40. Baxter NN, et al. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc. 2009;4.18. 57(3):403–11.
41. Du XL, Xia R, Hardy D. Relationship between chemotherapy use and cognitive impairments in older women with breast cancer: findings from a large population-based cohort. Am J Clin Oncol. 2010;1.907. 33(6):533–43.
42. Zotova E, et al. Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers Res Ther. 2010;2(1).
43. Jodeiri Farshbaf M, Ghaedi K. Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders? Biometals. 2017;30(1):1–16.
44. Sari Motlagh R, et al. The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2021;205(1):60–7.
45. Cui H, et al. Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24(1):15–23.
46. van Heemst D, et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol. 2005;40(1-2):11–5.
47. Yaffe MB, et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science. 1997;278(5345):1957–60.
48. Bao L, et al. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol. 2004;164(5):1727–37.
49. Segart L, et al. PIN1 promoter polymorphisms are associated with Alzheimer’s disease. Neurobiol Aging. 2007;28(1):69–74.
50. Lu J, et al. A novel functional variant (-842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis. 2009;30(10):1717–21.
51. Malik R, et al. Midlife vascular risk factors and risk of incident dementia: longitudinal cohort and Mendelian randomization analyses in the UK Biobank. Alzheimers Dement. 2021;17(9):1422–31.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.